Advertisement
Canada markets open in 6 hours 43 minutes
  • S&P/TSX

    21,656.05
    +13.18 (+0.06%)
     
  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     
  • DOW

    37,753.31
    -45.66 (-0.12%)
     
  • CAD/USD

    0.7275
    +0.0011 (+0.15%)
     
  • CRUDE OIL

    82.72
    +0.03 (+0.04%)
     
  • Bitcoin CAD

    83,737.98
    -4,209.31 (-4.79%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,392.70
    +4.30 (+0.18%)
     
  • RUSSELL 2000

    1,947.95
    -19.53 (-0.99%)
     
  • 10-Yr Bond

    4.5850
    0.0000 (0.00%)
     
  • NASDAQ futures

    17,758.25
    +99.75 (+0.56%)
     
  • VOLATILITY

    18.21
    -0.19 (-1.03%)
     
  • FTSE

    7,847.99
    +27.63 (+0.35%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • CAD/EUR

    0.6804
    +0.0002 (+0.03%)
     

Teva Presented New Data on Fremanezumab: What You Should Know

Teva Presented New Data on Fremanezumab: What You Should Know

During the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco, which was held from June 28 to July 1, Teva presented new data on its much-awaited migraine drug fremanezumab. Teva has a September PDUFA (Prescription Drug User Fee Act) date for the drug. On June 15, the company provided an update on the drug’s Enforce Phase 3 clinical development program for cluster headaches.